Table 5. Association between clinicopathological factors and axilla response (univariate analysis).
| Clinicopathological factors† | No. of patients (%) | Response of the Axilla | χ2/Z | P value | |
|---|---|---|---|---|---|
| No pCR, n (%) | pCR, n (%) | ||||
| Menstrual status‡ | 3.0393 | 0.2188 | |||
| Premenopausal | 436 (34.4) | 278 (63.8) | 158 (36.2) | ||
| Perimenopausal | 500 (39.4) | 292 (58.4) | 208 (41.6) | ||
| Postmenopausal | 332 (26.2) | 207 (62.3) | 125 (37.7) | ||
| Lesion side‡ | 1.8413 | 0.1748 | |||
| Left | 670 (53.0) | 422 (63.0) | 248 (37.0) | ||
| Right | 594 (47.0) | 352 (59.3) | 242 (40.7) | ||
| cT§ | ‒2.2675 | 0.0230* | |||
| T1 | 128 (10.1) | 71 (55.5) | 57 (44.5) | ||
| T2 | 898 (71.2) | 545 (60.7) | 353 (39.3) | ||
| T3 | 236 (18.7) | 158 (66.9) | 78 (33.1) | ||
| cN§ | ‒26.0720 | <0.0001*** | |||
| N0 | 467 (36.9) | 47 (10.1) | 420 (89.9) | ||
| N1 | 582 (45.9) | 526 (90.4) | 56 (9.6) | ||
| N2 | 166 (13.1) | 166 (100.0) | 0 (0.0) | ||
| N3 | 52 (4.1) | 38 (73.1) | 14 (26.9) | ||
| Histology (biopsy)‡ | 2.0936 | 0.1479 | |||
| Invasive Ductal | 1,240 (98.9) | 766 (61.8) | 474 (38.2) | ||
| Invasive Lobular | 14 (1.1) | 6 (42.9) | 8 (57.1) | ||
| Histological grade (biopsy)‡ | 71.9245 | <0.0001*** | |||
| I | 34 (2.7) | 25 (73.5) | 9 (26.5) | ||
| II | 727 (57.3) | 500 (68.8) | 227 (31.2) | ||
| III | 161 (12.7) | 105 (65.2) | 56 (34.8) | ||
| Unknown | 346 (27.3) | 147 (42.5) | 199 (57.5) | ||
| ER status (biopsy)‡ | 16.8017 | <0.0001*** | |||
| Negative | 494 (39.1) | 268 (54.3) | 226 (45.7) | ||
| Positive | 771 (60.9) | 507 (65.8) | 264 (34.2) | ||
| PR status (biopsy)‡ | 12.0626 | 0.0005*** | |||
| Negative | 680 (53.9) | 386 (56.8) | 294 (43.2) | ||
| Positive | 582 (46.1) | 386 (66.3) | 196 (33.7) | ||
| HER2 (biopsy)‡ | 0.1210 | 0.9413 | |||
| Negative | 635 (50.1) | 392 (61.7) | 243 (38.3) | ||
| Positive | 435 (34.3) | 264 (60.7) | 171 (39.3) | ||
| Unknown | 198 (15.6) | 121 (61.1) | 77 (38.9) | ||
| Ki67 expression (biopsy)‡ | 7.5982 | 0.0058** | |||
| Low | 346 (27.5) | 233 (67.3) | 113 (32.7) | ||
| High | 914 (72.5) | 538 (58.9) | 376 (41.1) | ||
| Course of CT (cycles)‡ | 0.0374 | 0.8466 | |||
| <5 | 1,175 (92.9) | 719 (61.2) | 456 (38.8) | ||
| ≥5 | 90 (7.1) | 56 (62.2) | 34 (37.8) | ||
| Regimen‡ | 0.8158 | 0.3664 | |||
| CT only | 1,242 (98.2) | 763 (61.4) | 479 (38.6) | ||
| CT + Anti-HER2 | 23 (1.8) | 12 (52.2) | 11 (47.8) | ||
†, Those clinicopathological factors with fewer than 10 patients were excluded in this analysis; ‡, Chi-squared test was used; §, Wilcoxon rank-sum test was used. *, P<0.05; **, P<0.01; ***, P<0.001. pCR, pathologic complete response; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; CT, chemotherapy.